Like the diagnostics divisions of Abbott Laboratories or Roche.

Similar to the diagnostic testing and instrument business of Becton Dickinson (BD).

• Clinical Laboratory Immunoassay & Chemistry Systems: Provides automated instruments and a broad menu of reagents for high-volume clinical laboratories, covering immunoassay and clinical chemistry diagnostics.
• Rapid Point-of-Care & Over-the-Counter Diagnostic Tests: Offers quick, accessible tests for infectious diseases like COVID-19, influenza, RSV, and strep, designed for immediate results in various settings.
• Transfusion Medicine Solutions: Supplies diagnostic systems and reagents for blood typing, donor screening, and cross-matching to ensure the safety and compatibility of blood transfusions.
• Molecular Diagnostics: Develops and manufactures systems and assays for the detection and quantification of nucleic acids, primarily used for infectious disease testing and pathogen identification.

QuidelOrtho (QDEL) primarily sells its diagnostic products and solutions to other companies and institutions within the healthcare sector, rather than directly to individual consumers.

Based on its public filings, QuidelOrtho does not identify any single named major customer (i.e., no customer accounts for 10% or more of its consolidated net revenues). This indicates a diversified customer base across the healthcare industry.

Its major customers, categorized by type of institution, include:

• Hospitals and Hospital Systems
• Clinical and Reference Laboratories
• Physician Offices and Clinics
• Healthcare Distributors

As these are categories of institutions rather than specific named public companies that meet a major customer threshold, no individual company symbols are applicable.

Brian J. Blaser, President and Chief Executive Officer

Mr. Blaser brings over 25 years of senior leadership experience in the in vitro diagnostics industry. Prior to joining QuidelOrtho, he spent 15 years at Abbott Laboratories, where he oversaw the company's diagnostics business, which included core laboratory, point-of-care, rapid, and molecular diagnostics. He also held key leadership roles in operations, finance, and engineering at companies such as Johnson & Johnson, Eastman Kodak, and General Motors. Mr. Blaser currently serves on the Board of Directors for the Advanced Medical Technology Association (AdvaMed), is a member of the Board of Trustees at the University of Dayton, and is a former board member of Quanterix and Meridian Bioscience. He took on the role of President and CEO of QuidelOrtho in May 2024, coming out of retirement.

Joseph M. Busky, Chief Financial Officer

Mr. Busky has over 30 years of experience in corporate finance roles for large, global companies across the diagnostics, medical devices, telecom, and marketing services industries. He has worked for both publicly owned companies and within private equity-owned settings. Before joining Ortho Clinical Diagnostics in July 2020, which later merged to form QuidelOrtho, Mr. Busky served as Chief Financial Officer for Vyaire Medical, Inc. His prior experience also includes serving as CFO of FDH Velocitel, CFO of InnerWorkings, Inc. for seven years, and holding corporate and divisional finance roles for 11 years at Siemens Medical Solutions Diagnostics/Dade Behring Holdings, Inc., Bayer Diagnostics, and Diagnostic Products Corporation, including Chief Accounting Officer at Dade Behring.

Phil McLellan, Chief Operations Officer

Mr. McLellan has led transformative efforts to expand QuidelOrtho's operational scope and capabilities. Prior to his current role, he spent 11 years at Thermo Fisher Scientific, where he led division operations teams for laboratory consumables, genetic analysis, and bioproduction businesses. He also held multiple global manufacturing roles over 12 years with Toyota Motor Manufacturing, where he developed expertise in lean manufacturing and process improvement.

Jonathan Siegrist, PhD, Executive VP of Research & Development and CTO

Dr. Siegrist is responsible for defining and executing the strategic vision for QuidelOrtho's molecular and point-of-care diagnostics portfolios. He leads the management of all functions of the business unit in all regions and is accountable for growing revenue and market share worldwide. Dr. Siegrist joined Quidel in 2010.

Lee Bowman, Chief Human Resources Officer

Mr. Bowman oversees all aspects of people, culture, and human resources strategy at QuidelOrtho. He previously served as Senior Vice President and Chief People Officer at RadNet, where he led initiatives in workforce engagement, diversity and inclusion, and leadership development. His expertise was further developed through significant roles at Edwards Lifesciences, Levi Strauss & Co., and Target.

The clear emerging threat to QuidelOrtho is the increasing development and market penetration of highly accurate, rapid, and often multiplexed molecular and immunoassay diagnostic platforms designed for decentralized, point-of-care, or even at-home use. These technologies, often leveraging advances in CRISPR, microfluidics, or advanced isothermal amplification, are capable of performing complex diagnostic analyses closer to the patient, thereby potentially challenging the traditional centralized laboratory model and some of QuidelOrtho's established point-of-care offerings by offering superior speed, expanded multiplexing capability, or greater ease of use outside of traditional lab environments.

QuidelOrtho (QDEL) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends, primarily focusing on its core diagnostic business and global expansion:

1. Growth in Core Diagnostic Platforms: The company anticipates continued growth from its core labs, immunohematology, and point-of-care segments. This includes stable renewal rates for its VITROS immunoassay platform and sustained demand for automated testing solutions, particularly from blood banks and hospitals. This growth specifically excludes COVID-19 and U.S. Donor Screening revenue impacts.
2. Launch and Expansion of New Diagnostic Products: QuidelOrtho is focused on launching innovative new products to enhance its portfolio. Recent examples include the FDA clearance of its high-sensitivity troponin assay for the VITROS platform, aimed at elevating cardiac testing capabilities, and the QUICKVUE Influenza + SARS Test. These new products are expected to drive long-term differentiation and recurring revenue streams.
3. Geographic Expansion and Increased International Penetration: The company is experiencing strong revenue growth in international markets, including EMEA (Europe, Middle East, and Africa), Latin America, Japan, and Asia-Pacific. QuidelOrtho sees significant opportunities for expansion in underpenetrated regions like China, particularly in clinical chemistry and immunoassays, where its differentiated technology is highly valued.
4. Adoption of Integrated and Automated Laboratory Solutions: QuidelOrtho is benefiting from an expanding installed base of integrated and automated lab systems. The company's commercial strategy emphasizes leading with integrated analyzers and automation, which drives consistent demand and recurring revenue from associated assays, reagents, and consumables.

Share Repurchases

• QuidelOrtho's board of directors authorized the repurchase of up to $300 million of the company's common stock over two years.
• For the fiscal year ended December 31, 2023, the company completed $7 million in share repurchases.

Share Issuance

• As part of the acquisition of Ortho Clinical Diagnostics by Quidel (which then merged into QuidelOrtho) in the first half of fiscal year 2022, Ortho shareholders received newly issued shares in the combined company, ultimately owning approximately 38%. This transaction had a total consideration of approximately $6.0 billion.
• For the trailing twelve months ended September 2025, QuidelOrtho reported $3 million in issuance of stock.

Outbound Investments

• Quidel (prior to the QuidelOrtho merger) acquired Ortho Clinical Diagnostics for approximately $6.0 billion in a transaction that closed in the first half of fiscal year 2022.
• In December 2023, QuidelOrtho invested in LEX Diagnostics, with the intent to acquire full ownership for approximately $100 million upon FDA clearance, which is anticipated in late 2025 or early 2026.

Capital Expenditures

• Capital expenditures totaled $191.4 million for the fiscal year ended December 31, 2023.
• Capital expenditures amounted to $195 million for the fiscal year ended December 31, 2024.
• The company prioritizes investments in research and development (R&D) and manufacturing capacity expansion, with expected expenditures focused on these areas and manufacturing facility expansions.